Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
120 hedge funds and large institutions have $290M invested in Concert Pharmaceuticals, Inc. in 2018 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 53 increasing their positions, 26 reducing their positions, and 24 closing their positions.
104% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 26
0% more call options, than puts
Call options by funds: $462K | Put options by funds: $462K
1.5% less ownership
Funds ownership: 75.1% → 73.6% (-1.5%)
2% less funds holding
Funds holding: 123 → 120 (-3)
13% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 24
27% less capital invested
Capital invested by funds: $399M → $290M (-$110M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$4.41M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4M |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$2.4M |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$2.23M |
| 5 |
Renaissance Technologies
New York
|
+$2.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
-$8.02M |
| 2 |
LCM
Laurion Capital Management
New York
|
-$4.06M |
| 3 |
SAM
Senzar Asset Management
New York
|
-$3.29M |
| 4 |
Allianz Asset Management
Munich,
Germany
|
-$2.63M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$2.3M |
CNCE Hedge Fund Activity: Q2 2018 in Review
120 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q2 2018, worth a combined $290M — down 27% from $399M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of CNCE and 21 opened new positions — a net loss of 3 holders — while 26 trimmed existing stakes and 53 added.
The largest buyer was Millennium Management, adding an estimated $4.41M. The largest seller was Ghost Tree Capital, exiting entirely with an estimated $8.02M sold.
- 120 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q2 2018, down from 123 in Q1 2018.
- Funds reported $290M of Concert Pharmaceuticals, Inc. stock for Q2 2018, down 27% quarter-over-quarter.
- 21 funds opened new Concert Pharmaceuticals, Inc. positions in Q2 2018 and 24 closed out, a net change of -3 holders.
- The largest Concert Pharmaceuticals, Inc. buyer in Q2 2018 was Millennium Management, an estimated $4.41M added.
- The largest Concert Pharmaceuticals, Inc. seller in Q2 2018 was Ghost Tree Capital, an estimated $8.02M sold.
Based on aggregated 13F filings for Q2 2018.